Clinical trial
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With…
NCT00032903 · Sigma-Tau Research, Inc., Industry · Completed
Key facts
| NCT number | NCT00032903 |
|---|---|
| Title | This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma. |
| Official title | Oral ST1481 in Adults With Malignant Glioma: a Phase I-II Clinical Trial |
| Lead sponsor | Sigma-Tau Research, Inc., Industry |
| Collaborators | Rhode Island Hospital |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Glioma |
| Intervention type | Drug |
| Interventions | Gimatecan® (ST 1481) |
| Enrollment | 59 |
| Start date | Mar 1, 2002 |
| Completion | Oct 1, 2005 |
| First posted | Apr 8, 2002 |
| Last update posted | Jun 3, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: